Search results
Showing 1 to 15 of 9026 results
In development Reference number: GID-HTE10067 Expected publication date: 19 May 2026
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]
In development Reference number: GID-TA10994 Expected publication date: 20 May 2026
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]
In development Reference number: GID-TA11572 Expected publication date: 21 May 2026
In development Reference number: GID-TA11232 Expected publication date: 21 May 2026
In development Reference number: GID-TA10726 Expected publication date: 13 May 2026
In development Reference number: GID-TA11023 Expected publication date: 28 May 2026
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]
In development Reference number: GID-TA11373 Expected publication date: 28 May 2026
In development Reference number: GID-TA11440 Expected publication date: 03 June 2026
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]
In development Reference number: GID-TA11091 Expected publication date: 04 June 2026
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]
In development Reference number: GID-TA11386 Expected publication date: 04 June 2026
Advanced breast cancer: diagnosis and management (Partial update)
In development Reference number: GID-NG10430 Expected publication date: 05 June 2026
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
This guideline sets out an antimicrobial prescribing strategy for insect and spider bites and stings in adults, young people and children aged 72 hours and over, including those that occurred while travelling outside the UK. It aims to limit antibiotic use and reduce antibiotic resistance.
View recommendations for NG182Show all sections
Behaviour change: digital and mobile health interventions (NG183)
This guideline covers interventions that use a digital or mobile platform to help people eat more healthily, become more active, stop smoking, reduce their alcohol intake or practise safer sex. The interventions include those delivered by text message, apps, wearable devices or the internet. The guideline only includes those that are delivered by the technology itself and not by healthcare professionals using technology to deliver interventions.
This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.